Covance Acquires Signet Laboratories
News Jun 01, 2006
"This acquisition strengthens Covance's leadership position in providing antibodies and detection reagents that support early drug development discovery work," said Joe Herring, Covance Chairman and CEO.
"These new service offerings will allow us to tap into commercial opportunities in the pharmaceutical and clinical diagnostics markets."
"We look forward to integrating these new products and services in our drug development portfolio, and in particular with our industry leading preclinical and central laboratory services."
"Signet's outstanding line of immunological diagnostic kits and reagents enhances Covances well-established line of antibodies for neuroscience, neurodegenerative disease research, and epitope tags," said Tony Cork, Corporate Senior Vice President and co-President of Early Development.
"We are excited to welcome Signet employees to Covance as they help us deliver enhanced solutions to our clients engaged in discovery and early-phase drug development studies."
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
You Are What Your Mother EatsNews
While many factors, such as the age of the mother, overall health and genetics ultimately play a role, the correlation between a mother’s nutrition habits and metabolism has been proved to directly impact the growth of her child. And researchers believe they may be one step closer to knowing why.READ MORE